Skip to main content

The Overdose Crisis Stopped Being Only About Opioids Years Ago. Treatment Still Hasn't Caught Up.

A new 86-source review lays out how fentanyl now travels with cocaine, meth, benzos and xylazine, and how few people get the one medicine we have.

ByThe Rize NewsroomNovember 15, 20262 min readCocaine

Somewhere in Florida in the last few years, 2,882 people died with cocaine in their bodies. In 2,499 of those deaths, cocaine was not the only drug present. That ratio, nearly nine in ten, is the quiet center of a review published this week in Frontiers in Public Health by a Florida International University team led by N.K. Mandapati with senior author S. Aggarwal. They read 86 studies and government reports from 2010 to 2026 and assembled the picture everyone working the front line already lives inside: fentanyl rarely travels alone anymore.

We are running a one-drug treatment system for a crisis where nearly everyone is using several.

The review’s numbers are blunt. Cocaine-involved overdose death rates more than tripled, from 1.4 to 4.5 per 100,000, between 2012 and 2018; meth-type stimulant deaths rose from 0.8 to 3.9. Benzodiazepines showed up in 21% of opioid overdose deaths in 2017, up from under 9% in 1999. The DEA found the animal sedative xylazine in 30% of seized fentanyl powder in 2023 and in fentanyl mixtures in 48 of 50 states. One caveat in fairness: this is a narrative review, a careful reading of other people’s data, not a new dataset, and the authors did no pooling or formal bias scoring. But the direction is not in dispute. We saw the same pattern in New York this week, where cocaine-only deaths are climbing among older Black men even as fentanyl’s share falls.

Now set that against the treatment numbers in the same paper. In 2022, of American adults who needed opioid use disorder treatment, 55.2% got any treatment and only 25.1% got medication. And for the stimulants riding alongside fentanyl, there is still no FDA-approved medication at all. NIDA’s own summary says the best-studied treatment for meth use disorder is contingency management, small rewards for negative drug tests, and it remains one of the hardest treatments in American addiction care to get paid for.

If you use cocaine or meth and think fentanyl is someone else’s problem, the data says otherwise. Carry naloxone anyway, test what you can, and do not use alone. Those are not opioid-user rules anymore.

For providers, here is the do-this-week move: stop sorting intake by “primary substance” and start asking every patient what else they use, and what they think might be in it. Offer naloxone to every stimulant patient, not just opioid patients. Ask your billing team, by Friday, whether your state Medicaid program pays for contingency management yet, and if not, who in your state is piloting it.

The review’s authors propose an “adaptive polysubstance response framework.” The simpler version is this: treat the person standing in front of you, not the drug on the form.

Filed Under

trendstreatmentpolicyPolysubstanceCocaineMethamphetamineXylazineContingency ManagementPeer-Reviewed ResearchOverdose

Keep up with the reporting.

One email each morning with the stories that put days like this in context.

A daily, no-spam briefing. Unsubscribe anytime.

Continue reading

More from this section